Welcome to our dedicated page for Avalon GloboCare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalon GloboCare Corp. filings document public-company disclosures for its consumer diagnostics, generative AI software, intellectual property, and capital structure. Recent 8-K reports cover material events involving Avalon Quantum AI LLC, the Catch-Up AI video platform, Nasdaq listing-compliance notices, shareholder communications, and pro forma financial information tied to the completed sale of Avalon RT 9 Properties, LLC.
The company’s proxy and registration filings describe board elections, auditor ratification, equity incentive-plan matters, advisory compensation votes, Nasdaq-rule approvals for warrant share issuance, and securities registration matters. Avalon’s filings also address common stock, warrants, pre-funded warrants, shareholder voting mechanics, governance procedures, operating and financial results, and risk disclosures for a smaller reporting company.
Avalon GloboCare (Nasdaq: ALBT) filed an 8-K disclosing a definitive agreement dated June 23 2025 with subsidiary Q&A Distribution and Qi Diagnostics to co-develop a volatile-organic-compound breathalyzer for THC screening.
The four-stage project requires Q&A to fund up to $975,000 in milestone payments: $95k (stage 1), $180k (stage 2), $300k (stage 3) and $400k (stage 4).
In return, Q&A earns a passive financial interest in the resulting intellectual property, escalating from 6% after milestone 1 to 50% if all milestones are met; Qi Diagnostics retains operational control of the IP.
Either party may terminate on 30-days notice, but vested IP interests survive. No revenue projections, regulatory approvals or guidance were provided. Exhibits 10.1 and 99.1 contain the full agreement and press release.